In last trading session, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) saw 1.7 million shares changing hands with its beta currently measuring 1.70. Company’s recent per share price level of $3.14 trading at $0.14 or 4.67% at ring of the bell on the day assigns it a market valuation of $223.29M. That closing price of ZNTL’s stock is at a discount of -500.32% from its 52-week high price of $18.85 and is indicating a premium of 9.87% from its 52-week low price of $2.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.15 million shares which gives us an average trading volume of 1.76 million if we extend that period to 3-months.

For Zentalis Pharmaceuticals Inc (ZNTL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.11. Splitting up the data highlights that, out of 10 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.91 in the current quarter.

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information

Upright in the green during last session for gaining 4.67%, in the last five days ZNTL remained trading in the green while hitting it’s week-highest on Friday, 10/18/24 when the stock touched $3.14 price level, adding 0.32% to its value on the day. Zentalis Pharmaceuticals Inc’s shares saw a change of -79.27% in year-to-date performance and have moved 5.02% in past 5-day. Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) showed a performance of -27.98% in past 30-days. Number of shares sold short was 8.64 million shares which calculate 2.4 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 68.6% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 55. It follows that stock’s current price would drop -27.39% in reaching the projected high whereas dropping to the targeted low would mean a loss of -27.39% for stock’s current value.

Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts

Statistics highlight that Zentalis Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -75.77% of value to its shares in past 6 months, showing an annual growth rate of 32.44% while that of industry is 17.20. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -50.05% during past 5 years.

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders

Insiders are in possession of 3.48% of company’s total shares while institution are holding 108.18 percent of that, with stock having share float percentage of 112.08%. Investors also watch the number of corporate investors in a company very closely, which is 108.18% institutions for Zentalis Pharmaceuticals Inc that are currently holding shares of the company. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the top institutional holder at ZNTL for having 13.96 million shares of worth $57.1 million. And as of 2024-06-30, it was holding 19.6902 of the company’s outstanding shares.

The second largest institutional holder is FMR LLC, which was holding about 8.68 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.2383 of outstanding shares, having a total worth of $35.49 million.